Rodman & Renshaw Outperform On Enzo Biochem

Rodman & Renshaw has an Outperform rating and a $7 price target on shares of Enzo Biochem Inc ENZ. In a note to clients, Rodman & Renshaw writes, "We are reiterating our Market Outperform / Speculative Risk rating and 12-month target price of $7, based on a 2015 discounted earnings per share and revenues per share analysis. In keeping with our thesis, we believe there exists potential for additional novel diagnostic tests such as ColonSentry and HPV OncoTect to be in-licensed in 2011 and 2012. Enzo has the potential to generate value for the long-term investor interested in a fundamental revenue story." Shares of ENZ are up 1 cent to $3.72 today on less than 29,000 shares.